MétaCan
Menu
← Back to cohort

S102 The potential effect of glucagon-like peptide 1 receptor agonists (GLP1s) on chronic obstructive pulmonary disease (COPD) exacerbations, a case control analyses

2025· article· W4416101811 on OpenAlexaff
Bernardino Alcázar Navarrete, Heath Heatley, A Kaplan, T.Y. Lee, Mariko Siyue Koh, Naveed Sattar, John Townend, Derek Skinner, V Carter, D. Price

Bibliographic record

Venuenot available
Typearticle
Language
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsTD Bank Group
Fundersnot available
KeywordsCOPDExacerbationCohortCase-control studyPopulationMedical prescriptionCohort studyBody mass indexType 2 diabetes

Abstract

fetched live from OpenAlex

Introduction Reducing the risk of exacerbations is a key objective of COPD management. Recently published studies have demonstrated that GLP-1RAs used for weight loss also have benefits on respiratory outcomes within asthma.1 Aims The aim of this study was to use real-world data from the Optimum Patient Care Research Database (OPCRD) to determine whether respiratory benefits might extend to a COPD population & Type 2 Diabetes. Methods Our exposed cohort were prescribed a GLP-1RA, and had a diagnosis of COPD, type 2 diabetes, were over 40 years old at the time of the first GLP-1RA (index date). We identified an age, sex, smoking status and BMI matched control cohort of patients with COPD and diabetes who were contributing data to OPCRD at the time of their matched patients index date, their COPD treatments and number of exacerbations in the year prior to the GLP-1RA prescription. Exacerbation outcomes included a) specific exacerbation measure (chest infection type diagnosis with an antibiotic or steroid prescription), b) sensitive exacerbation measure (antibiotic or steroid prescription without a chest infection type diagnosis), c) OCS prescriptions and d) hospital admissions in the year following GLP1 initiation. Results The cases mean age was 66, 58% were male, the mean BMI was 36.25. Cases GOLD (2023) group classification were 16% A, 55% B, and 29% E. Controls were comparable. Patients receiving a GLP-1RAs had significantly lower risk of exacerbations (specific IRR 0.84: 0.79–0.89 p<0.001, sensitive IRR 0.89: 0.84–0.95 p=0.003). Cases had lower OCS prescriptions (IRR 0.86: 0.77–0.95 p<0.001) and respiratory hospitalisations (IRR 0.61: 0.41–0.74 p<0.001) compared with controls. Conclusions This real-world study provides evidence that GLP-1RAs therapy maybe associated with a lower risk of COPD exacerbations in patients with comorbid T2D suggesting a potential protective effect of GLP-1 RAs on respiratory health. Furthermore, an approximately 20% lower risk in exacerbations and corticosteroid prescriptions, is clinically meaningful, especially in a population with high multimorbidity burden. Large scale randomised trials are now needed to test this potential. Reference Kaplan A, Heatley H, Townend J, et al. The real-world impact of glucagon-like peptide 1 receptor agonists on asthma control in people with high-risk asthma and obesity. Adv Ther. 2025.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.013
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.012
Threshold uncertainty score0.040

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.013
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.003
Bibliometrics0.0020.002
Science and technology studies0.0010.000
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0120.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.010
GPT teacher head0.289
Teacher spread0.279 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same topicDiabetes Treatment and Management→French-language works237,207→